Methods of diagnosis and treatment involving nitrite

Abstract

Methods and therapeutics for treating nitric oxide (NO) mediated conditions comprising administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic, wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via diallyl disulfide (DADS), and the NO mediated condition includes one of inflammation, wound healing, and an infection.

Wherefore, I/We claim: 
     
         1 . A method of treating nitric oxide (NO) mediated condition comprising:
 administering a therapeutically effective amount of a pharmaceutical composition containing a therapeutic;   wherein the therapeutic one of increases xanthine oxidase (XO) associated nitrite conversion to nitric oxide and increases nitrite conversion to nitric oxide via diallyl disulfide (DADS); and   the NO mediated condition includes one of inflammation, wound healing, and an infection.   
     
     
         2 . The method of  claim 1  wherein the therapeutic increases XO associated nitrite conversion to nitric oxide and the therapeutic includes diallyl trisulfide (DATS) or a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or combination thereof. 
     
     
         3 . The method of  claim 2  wherein the pharmaceutical composition further includes one of XO, nitrite, both XO and nitrite, and pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or combinations thereof. 
     
     
         4 . The method of  claim 1  wherein the therapeutic increases nitrite conversion to nitric oxide via DADS and the therapeutic includes DADS or a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or combination thereof. 
     
     
         5 . The method of  claim 4  wherein the pharmaceutical composition further includes one of nitrite and a pharmacologically acceptable salt, solvate, ester, amide, clathrate, stereoisomer, enantiomer, prodrug or analog thereof, or combination thereof. 
     
     
         6 . The method of  claim 1  wherein the therapeutic includes a nanoformulation compound. 
     
     
         7 . The method of  claim 6  wherein the nanoformulation compound is in one of a cream and a lotion. 
     
     
         8 . The method of  claim 1  wherein the NO mediated condition includes inflammation. 
     
     
         9 . The method of  claim 1  wherein the NO mediated condition includes wound healing. 
     
     
         10 . The method of  claim 1  wherein the NO mediated condition includes an infection. 
     
     
         11 . The method of  claim 1  wherein the pharmaceutical composition further includes one of L-propionyl-carnitine, Prostaglandin E1, and aspirin. 
     
     
         12 . The method of  claim 1  wherein the pharmaceutical composition further includes compounds that increase NO levels. 
     
     
         13 . The method of  claim 12  wherein the pharmaceutical composition that increases NO levels is sodium nitrite.